$CL

CL's Q2 Revenues Rise 4.9%: Can Growth Hold Amid Global Volatility?

Colgate-Palmolive (CL) reported Q2 2026 revenues of $5.36B, up 4.9% YoY, with EPS of 99 cents and free cash flow up 18%. Organic sales rose in most divisions, led by emerging markets. Gross margin increased 100 bps YoY. Management expects more volume-driven growth in H2 as costs and tariffs rise.

Original reporting
Published Aug 18, 2026, 3:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CL's Q2 Revenues Rise 4.9%: Can Growth Hold Amid Global Volatility? — source image
Decision brief

The 30-second read

$CLBullishMed
01

Why it matters

Traders can use the reported margin and free-cash-flow improvements to reassess near-term earnings power, while monitoring whether U.S. promotional and targeted pricing actions translate into volume stabilization as cost and tariff pressures increase.

02

Market read

A results-and-outlook update for CL with concrete Q2 financial metrics and explicit H2 cost/tariff and U.S. trajectory risks.

03

What to watch

The article notes management expects growth to become more volume-driven in H2 while costs/tariffs rise, which increases the risk that margin gains fade if volume recovery does not materialize.

Relevance 7/10Novelty 6/10Timing: after-hours/near-term positioning following Q2 results and H2 commentary

Background

The piece frames Colgate-Palmolive’s Q2 performance against global volatility, emphasizing organic growth across divisions/categories and geographic diversification.

Company-level read

Ticker impact

$CLBullishMedium confidence
Context

Colgate-Palmolive reports Q2 2026 revenues of $5.36B, up 4.9% YoY, with gross margin expansion and higher free cash flow.

Expected impact

Moderate positive bias for the stock on results quality, with follow-through dependent on whether U.S. promotional actions stabilize volume in H2.

Evidence & confidence

The article provides multiple concrete operating metrics (revenue growth, gross margin +100 bps YoY, FCF +18%) plus explicit H2 headwinds (tariffs and raw-material costs rising, U.S. weakness). However, it does not provide a new forward guidance range or a fresh market-moving event beyond the reported quarter.

Market effects

Supports the consumer staples narrative that pricing and productivity can offset cost pressure, but highlights that U.S. volume softness remains a key differentiator.

Emerging markets strength (India, Brazil, Mexico, China) may reinforce relative outperformance for globally diversified staples names.

Tariff and raw-material cost risk flagged for H2 can influence broader staples margin expectations if costs continue to rise.

Counterpoint

The headline revenue growth may mask volume fragility, especially with U.S. weakness and a private-label exit creating volume drag that could reappear in H2.

Key entities

  • Colgate-Palmolive Company

    Subject of the article, reporting Q2 2026 revenue growth, margin expansion, and higher free cash flow, with H2 headwinds in the U.S. and rising costs/tariffs.

Related articles

$CLMed

Colgate-Palmolive India Taps A Kenvue Exec As CEO

Colgate-Palmolive India appointed a former Kenvue executive as CEO, who previously worked at Colgate-Palmolive for nearly 13 years. The outgoing CEO will take a regional marketing role. During her tenure, the stock outperformed the Nifty FMCG index, but shares fell 1% after the announcement. The company's e-commerce sales are over 50% premium products, which can impact pricing and costs.

$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.